Cardiologist Says FDA Is 'Late to the Show' on Teen Vaping Crisis
*By Carlo Versano*
The shocking rise in teen vaping is a public health crisis that the FDA has been slow to address, according to a nationally recognized cardiologist.
Dr. Kevin Campbell, who is also CEO of Pace Mate, a digital cardiac monitoring service, said the [recent study](https://www.cnbc.com/2019/02/11/e-cigarettes-single-handedly-drives-spike-in-teen-tobacco-use-cdc.html) from the CDC that linked vaping to a spike in teen tobacco use shows that more serious steps need to be take. The first step? Get rid of the flavored nicotine "pods," which Campbell said are acting as a gateway for teenage beginner vapers to get hooked on nicotine.
"We don't know the long-term health effects yet," Campbell said. "I can't emphasize that enough."
While popular vape products are unarguably "healthier" than combustible cigarettes, they still involve the delivery of an addictive drug (nicotine), that is known to do damage to the heart and blood vessels. And there is not enough data on the additives and preservatives that go into the pods.
"They may be doing deleterious things to our bodies as well," Campbell said.
One in five American high schoolers now vapes, according to the CDC, which is enough to cause alarm at the FDA. That agency recently announced a crackdown on vaping companies that market to teens, but that's not enough, in Campbell's opinion.
"I think the FDA is a little bit late to the show here," he said. It's going to require a national education program ー think D.A.R.E. for a new era ー that explains the unknowns and risks involved in vaping. "We need to get ahead of it," Campbell said.
For full interview [click here](https://cheddar.com/videos/teen-tobacco-product-use-on-the-rise).
Stocks closed lower Thursday amid continued volatility. The S&P 500 was down 10% from its record high, the Dow was down 7%, and the Nasdaq was 4% away from bear market territory as it closed 16% below its record high. Investors are still processing this week's Federal Reserve announcement about a potential first rate hike in March. Chris Gaffney, President of World Markets at TIAA Bank, joins Cheddar News' Closing Bell to discuss today's close, the Fed's announcement, predictions about interest rate hikes, and more.
Low-code app development platform Crowdbotics raised $22 million in a Series A funding round led by Jackson Square Ventures. Crowdbotics has helped more than 14,000 customers launch apps without having to learn how to code. The company can offer a team of expert developers to help companies launch custom apps, or provide the means for companies to develop apps themselves. Crowdbotics CEO Anand Kulkarni joined Cheddar News' Closing Bell to discuss.
Comcast announced that the company has beaten its projected earnings for Q4. However, the telecommunications giant fell short of its predictions for customer growth.
Kim Kardashian’s shapewear brand Skims has doubled its valuation to $3.2 billion. Investors have taken a bet on the success of this brand in the form of fresh funds for the two-year-old company.
McDonald's missed on both the top and bottom lines in its Q4 earnings, marking the fourth loss for the fast-food giant in the past eight quarters. It comes as higher costs from food to wages ate into the blue-chip company's profits. George Seay, CEO of investment advisor Annandale Capital, joined Wake Up with Cheddar to discuss the recent numbers and the better-than-expected success of the McPlant burger made with plant-based Beyond Meat. "They're changing with the times, and they have to," Seay noted. "You can just sell a Big Mac to everybody. There's a lot of people who don't want to eat a Big Mac anymore."
Moderna launched a clinical trial of a COVID-19 booster shot specifically targeting the omicron variant. The first participant has already received a dose, and Moderna expects to enroll about 600 adults total, split between two groups. In the first group, participants will have previously received two doses of the Moderna vaccine, and in the second, participants will have received its booster. Dr. Paul Burton, chief medical officer at Moderna, joined Cheddar’s Opening Bell to discuss the trial, yearly boosters, and what lies ahead for the company.
